Marathon Pharma DMD drug candidate Fast Track'd

• The FDA grants Fast Track status to privately-held Marathon Pharmaceuticals' corticosteroid MP-104 (deflazacort) for the treatment of Duchenne Muscular Dystrophy (DMD).
• Fast Track status provides for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).
• DMD-related tickers: (NASDAQ:SRPT) (NASDAQ:PTCT) (NYSE:PFE) (NASDAQ:RNA) (NASDAQ:MRNA) (NASDAQ:ROSG-OLD)